Skip to main content
SpringerLink
Log in

Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Antipsychotics are the mainstay of the long-term treatment of patients with schizophrenia. In this context, the evidence also supports the effectiveness of long-acting injections (LAIs) or depots of antipsychotics regarding their relapse-preventing properties. When a LAI formulation of risperidone was launched as the first second-generation depot, there was a renaissance of interest in these formulations. In the meantime, olanzapine, paliperidone, and aripiprazole have been approved by regulatory authorities as LAIs in various countries. All studies using the new-generation depots have shown a clear advantage over placebo regarding relapse prevention and symptom reduction. Safety profiles of the long-acting compounds are comparable to their oral formulations with the exception of olanzapine pamoate injections, which can sometimes lead to a post-injection delirium. Despite the fact that many treatment guidelines recommend LAI antipsychotics as an important treatment option for the long-term management of schizophrenia, they are still most frequently used in chronically ill patients with considerable compliance problems. It is imperative to overcome this indication bias in order to be able to utilize all available treatment options in the long-term management of schizophrenia. There is little evidence on comparisons between LAIs and their oral mother compounds, and even less concerning effectiveness comparisons between different depots. The purpose of this manuscript is to review the recent clinical evidence on new-generation depot antipsychotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71(Suppl 2):20–6.

    Article  PubMed  Google Scholar 

  2. Patel MX, Nikolaou V, David AS. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003;33(1):83–9.

    Article  PubMed  CAS  Google Scholar 

  3. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948–53.

    Article  PubMed  Google Scholar 

  4. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113–32.

    Article  PubMed  CAS  Google Scholar 

  5. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–32.

    Article  PubMed  Google Scholar 

  6. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharm. 2005;15(1):111–7.

    Article  CAS  Google Scholar 

  7. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241–9.

    Article  PubMed  Google Scholar 

  8. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250–7.

    Article  PubMed  CAS  Google Scholar 

  9. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatr Suppl. 2009;52:S29–36.

    Article  Google Scholar 

  10. Fleischhacker WW, Gopal S, Lane R, et al. A Randomized Trial of Paliperidone Palmitate and Risperidone Long-Acting Injectable in Schizophrenia. Int J Neuropsychopharmacol. p. 1–12. [Epub 2011 Jul 22].

  11. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress Neuro-Psychopharm. 2011;35(1):218–26.

    Article  CAS  Google Scholar 

  12. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry. 2010;7(11):23–31.

    PubMed  Google Scholar 

  13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.

    Article  PubMed  CAS  Google Scholar 

  14. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9.

    Article  PubMed  Google Scholar 

  15. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367–77.

    Article  PubMed  CAS  Google Scholar 

  16. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med. 2002;346(1):16–22.

    Article  PubMed  CAS  Google Scholar 

  17. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011;364(9):842–51.

    Article  PubMed  CAS  Google Scholar 

  18. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9.

    PubMed  CAS  Google Scholar 

  19. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177–83.

    Article  PubMed  CAS  Google Scholar 

  20. Quiroz JA, Rusch S, Thyssen A, et al. Deltoid Injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci. 2011;8(6):20–8.

    PubMed  Google Scholar 

  21. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic schizophrenia treatment adherence registry (e-STAR). Eur Psychiatry. 2009;24(5):287–96.

    Article  PubMed  Google Scholar 

  22. Guy W. Ecdeu assessment manual for psychopharmacology. Revised ed. Rockville, MD: National Institute of Mental Health; 1976. p. 218–22.

  23. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766–71.

    Article  PubMed  CAS  Google Scholar 

  24. Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the source study results. BMC Psychiatry. 2011;11:167.

    Article  PubMed  Google Scholar 

  25. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia: III. Five-year outcome and its predictors. Arch Gen Psychiatry. 1977;34(2):159–63.

    Article  PubMed  CAS  Google Scholar 

  26. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  27. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011;10:10.

    Article  PubMed  Google Scholar 

  28. Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012;73(5):669–75. [Epub 2012 March 6].

    Google Scholar 

  29. Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70(10):1397–406.

    Article  PubMed  CAS  Google Scholar 

  30. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20(2):297–310.

    Article  PubMed  CAS  Google Scholar 

  31. Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325–31.

    Article  PubMed  Google Scholar 

  32. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the cohort for the general study of schizophrenia (CGS). Schizophr Res. 2012;134(2–3):187–94.

    Article  PubMed  Google Scholar 

  33. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl. 20:22–33;quiz 4-57.

    Google Scholar 

  34. Wiffen BD, Rabinowitz J, Fleischhacker WW, et al. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses. 2010;4(3):169–75.

    Article  PubMed  Google Scholar 

  35. Mintz AR, Addington J, Addington D. Insight in early psychosis: a 1-year follow-up. Schizophr Res. 2004;67(2–3):213–7.

    Article  PubMed  Google Scholar 

  36. Lysaker PH, Bell MD, Bryson G, et al. Personality as a predictor of the variability of insight in schizophrenia. J Nerv Ment Dis. 1999;187(2):119–22.

    Article  PubMed  CAS  Google Scholar 

  37. Parellada E, Kouniakis F, Siurkute A, et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149–54.

    Article  PubMed  Google Scholar 

  38. Rossi A, Bagala A, Del Curatolo V, et al. Remission in schizophrenia: one-year italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009;24(7):574–83.

    Article  PubMed  CAS  Google Scholar 

  39. Emsley R, Oosthuizen PP, Koen L, et al. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73(4):e541–7.

    Article  PubMed  CAS  Google Scholar 

  40. Lloyd K, Latif MA, Simpson S, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol. 2010;25(3):243–52.

    Article  PubMed  CAS  Google Scholar 

  41. Schmauss M, Diekamp B, Gerwe M, et al. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry. 2010;43(2):73–80.

    Article  PubMed  CAS  Google Scholar 

  42. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8):1084–9.

    Article  PubMed  CAS  Google Scholar 

  43. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20(3):121–30.

    Article  PubMed  Google Scholar 

  44. Llorca PM, Sacchetti E, Lloyd K, et al. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther. 2008;46(1):14–22.

    PubMed  CAS  Google Scholar 

  45. Kissling W, Glue P, Medori R, et al. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol. 2007;22(8):505–13.

    Article  PubMed  CAS  Google Scholar 

  46. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009;120(2):97–101.

    Article  PubMed  CAS  Google Scholar 

  47. Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig. 2010;30(11):777–87.

    Article  PubMed  CAS  Google Scholar 

  48. De la Gandara J, San Molina L, Rubio G, et al. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the sphere study. Expert Rev Neurother. 2009;9(10):1463–74.

    Article  PubMed  Google Scholar 

  49. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–9.

    Article  PubMed  Google Scholar 

  50. Thyssen A, Rusch S, Herben V, et al. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50(9):1011–21.

    Article  PubMed  CAS  Google Scholar 

  51. Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res. 2011;132(1):35–41.

    Article  PubMed  Google Scholar 

  52. Surguladze SA, Chu EM, Marshall N, et al. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. J Psychopharmacol. 2011;25(6):722–33.

    Article  PubMed  CAS  Google Scholar 

  53. Morris JS, Frith CD, Perrett DI, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature. 1996;383(6603):812–5.

    Article  PubMed  CAS  Google Scholar 

  54. Phillips ML, Young AW, Senior C, et al. A specific neural substrate for perceiving facial expressions of disgust. Nature. 1997;389(6650):495–8.

    Article  PubMed  CAS  Google Scholar 

  55. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–54.

    Article  PubMed  CAS  Google Scholar 

  56. Rabinowitz J, Napryeyenko O, Burba B, et al. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol. 2011;31(1):75–81.

    Article  PubMed  CAS  Google Scholar 

  57. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470–84.

    Article  PubMed  CAS  Google Scholar 

  58. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363–70.

    Article  PubMed  CAS  Google Scholar 

  59. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1–3):117–30.

    Article  PubMed  Google Scholar 

  60. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6–14.

    Article  PubMed  CAS  Google Scholar 

  61. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1–3):147–61.

    Article  PubMed  CAS  Google Scholar 

  62. Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64(2):216–39.

    Article  PubMed  CAS  Google Scholar 

  63. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–47.

    Article  PubMed  CAS  Google Scholar 

  64. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247–56.

    Article  PubMed  Google Scholar 

  65. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–17.

    Article  PubMed  Google Scholar 

  66. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685–97.

    Article  PubMed  CAS  Google Scholar 

  67. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–82.

    Article  PubMed  CAS  Google Scholar 

  68. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235–44.

    Article  PubMed  CAS  Google Scholar 

  69. Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002–8.

    Article  PubMed  CAS  Google Scholar 

  70. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022–31.

    Article  PubMed  CAS  Google Scholar 

  71. Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12.

    Article  PubMed  Google Scholar 

  72. Bossie CA, Sliwa JK, Ma YW, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry. 2011;11:79.

    Article  PubMed  CAS  Google Scholar 

  73. Sliwa JK, Bossie CA, Ma YW, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res. 2011;132(1):28–34.

    Article  PubMed  Google Scholar 

  74. Gopal S, Pandina G, Lane R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci. 2011;8(8):26–33.

    PubMed  Google Scholar 

  75. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585–600.

    Article  PubMed  CAS  Google Scholar 

  76. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553–64.

    Article  PubMed  CAS  Google Scholar 

  77. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140–50.

    Article  PubMed  CAS  Google Scholar 

  78. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790–9.

    Article  PubMed  CAS  Google Scholar 

  79. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181–9.

    Article  PubMed  Google Scholar 

  80. Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry. 2011;11:152.

    Article  PubMed  Google Scholar 

  81. Witte MM, Case MG, Schuh KJ, et al. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin. 2012;28(3):315–23.

    Article  PubMed  CAS  Google Scholar 

  82. McDonnell DP, Kryzhanovskaya LA, Zhao F, et al. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol. 2011;26(6):422–33.

    PubMed  CAS  Google Scholar 

  83. Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry. 2011;11:28.

    Article  PubMed  CAS  Google Scholar 

  84. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011;26(1):35–42.

    Article  PubMed  Google Scholar 

  85. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: I. Analysis of cases. BMC Psychiatry. 2010;10:43.

    Article  PubMed  Google Scholar 

  86. McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: II. Investigations of mechanism. BMC Psychiatry. 2010;10:45.

    Article  PubMed  Google Scholar 

  87. Ascher-Svanum H, Peng X, Montgomery W, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry. 2011;26(5):313–9.

    Article  PubMed  CAS  Google Scholar 

  88. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298–304.

    Article  PubMed  CAS  Google Scholar 

  89. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005;6(12):2091–101.

    Article  PubMed  CAS  Google Scholar 

  90. Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs. 2008;22(4):335–52.

    Article  PubMed  CAS  Google Scholar 

  91. Fleischhacker W. Pharmacokinetic study of once-monthly aripiprazole intramuscular depot in adult patients with schizophrenia [poster]. In: 164th annual meeting of the American Psychiatric Association; 2011 May 14–18; Honolulu.

  92. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617–24.

    Article  PubMed  CAS  Google Scholar 

  93. Guy W. AIMS: ECDEU assessment manual for psychopharmacology. Washington, DC: Government Printing Office; 1976.

    Google Scholar 

  94. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–9.

    Article  PubMed  CAS  Google Scholar 

  95. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–6.

    Article  PubMed  CAS  Google Scholar 

  96. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole. Poster presented at the ACNP 2012 Annual Meeting, Dec 2012, Hollywood, FL.

  97. Kwatra SG, Batson NE, Kramer SI. Long-acting risperidone and oral antipsychotics in schizophrenia. New Engl J Med. 2011;364(23):2264–5 author reply 265-6.

    Article  PubMed  CAS  Google Scholar 

  98. Suzuki T. Long-acting risperidone and oral antipsychotics in schizophrenia. N Engl J Med. 2011;364(23):2265 author reply 265-6.

    PubMed  CAS  Google Scholar 

  99. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191:131–9.

    Article  PubMed  Google Scholar 

  100. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.

    Article  PubMed  Google Scholar 

  101. Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–82.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

There was no direct or indirect funding for this manuscript. WF has received research grants from Janssen and Otsuka and consultancy and speaker honoraria from the same companies. AR has no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Biological Psychiatry Division, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria

    Anna-Sophia Rauch & W. Wolfgang Fleischhacker

  2. Department of Psychiatry and Psychotherapy, General and Social Psychiatry Division, Medical University Innsbruck, Innsbruck, Austria

    W. Wolfgang Fleischhacker

Authors
  1. Anna-Sophia Rauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Wolfgang Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna-Sophia Rauch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rauch, AS., Fleischhacker, W.W. Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective. CNS Drugs 27, 637–652 (2013). https://doi.org/10.1007/s40263-013-0083-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-013-0083-9

Keywords

Search

Navigation